Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting
San Diego, CA, USA – May 1, 2013 –
The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego, CA:
Androgen deprivation therapy by a gonadotropin releasing hormone antagonist, degarelix, lowers the risk of cardiovascular events or death when compared to luteinising hormone-releasing agonists
Date: Monday, May 6, 2013; 8:00-10:00 AM
Session/Type: Prostate Cancer: Advanced (II); Moderated Poster
Location: San Diego Convention Center, Room 7
Authors: Peter Albertsen; Bertrand Tombal; Thomas Wiegel; Egbert van der Meulen; Bo-Eric Persson; Tine Kold Olesen; Joshua Beckman
Analysis of disease control-related outcomes from six comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists
Date: Sunday, May 5, 2013; 3:30-5:30 PM
Session/Type: Prostate Cancer: Advanced (I); Podium Presentation
Location: San Diego Convention Center, Room 1
Authors: Neal Shore; Kurt Miller; Bertrand Tombal; E. David Crawford; Cathrina Karup; Egbert van der Meulen; Bo-Eric Persson
Per AUA media embargo policy, coverage of research being presented is prohibited before the date and time of presentation.
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries.
To learn more about Ferring or its products, please visit www.ferring.com.